Hera’s preclinical oncology products & services seamlessly integrate into and enhance existing programs from basic research and target discovery to lead optimization and development. In vitro and in vivo gene editing using our core platforms piggyBac transposase and Cas-CLOVER enable genetic model creation. Cancer cell lines and patient derived xenografts (PDX) models can be screened in vitro or engrafted into the OncoRat, a unique fully SCID rat offering a reliable, efficient & robust complement to mouse xenograft models. OncoRat consistently demonstrates high efficiency and desirable uniformity in tumor model growth profiles. Larger sample sizes enable robust downstream analysis and pairs well with nonclinical rat safety models, reducing the need for cross-species assessment. Our unique immuno-oncology services are currently offered in the NSG mouse while we continue to develop a humanized rat on the SRG platform.